CD34+CD38-白血病干细胞频率预测急性髓系白血病转归
在HOVON102/SAKK试验的附加研究中,用流式细胞术检测CD34+CD38-白血病干细胞(LSC)。诊断时LSC频率独立预测总生存(OS);缓解后联合微小残留病(MRD)与LSC,MRDhigh/LSChigh组较MRDlow/LSClow组OS风险比3.62、累积复发率风险比5.89。
要点
- 诊断时CD34+CD38- LSC频率独立预测急性髓系白血病总生存。
- 完全缓解后联合MRD与LSC可识别预后极差亚组:MRDhigh/LSChigh组OS风险比3.62、累积复发率风险比5.89。
- 在NPM1突变阳性亚组,流式细胞术联合qPCR检测NPM1-MRD可改善预后评估。
核心结论
- 这是首个前瞻性研究证明LSC可显著增强MRD检测的预后价值,识别出治疗失败概率接近100%的患者亚组,值得考虑将LSC检测纳入未来AML风险分层方案。
研究设计与样本
- HOVON102/SAKK试验的附加研究,用流式细胞术检测含CD34+CD38-组分的LSC,前瞻性评估预设截断值。
- 诊断时评估CD34+CD38- LSC水平(n=594),在形态学完全缓解(CR)的骨髓中识别LSClow/LSChigh(n=302)和MRDlow/MRDhigh(n=305)。
- 242例CR患者同时具备MRD和LSC结果。
主要发现
- 诊断时CD34+CD38- LSC频率独立预测总生存(OS)。
- 达到CR后,联合LSC与MRD显示:MRDhigh/LSChigh患者较MRDlow/LSChigh、MRDhigh/LSClow、尤其MRDlow/LSClow患者生存降低(OS风险比3.62,累积复发率风险比5.89)。
- 在NPM1突变阳性亚组,流式细胞术方法联合qPCR检测NPM1-MRD可改善预后评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current risk algorithms are primarily based on pre-treatment factors and imperfectly predict outcome in acute myeloid leukemia (AML). We introduce and validate a post-treatment approach of leukemic stem cell (LSC) assessment for prediction of outcome. LSC containing CD34+CD38- fractions were measured using flow cytometry in an add-on study of the HOVON102/SAKK trial. Predefined cut-off levels were prospectively evaluated to assess CD34+CD38-LSC levels at diagnosis (n = 594), and, to identify LSClow/LSChigh (n = 302) and MRDlow/MRDhigh patients (n = 305) in bone marrow in morphological complete remission (CR). In 242 CR patients combined MRD and LSC results were available. At diagnosis the CD34+CD38- LSC frequency independently predicts overall survival (OS). After achieving CR, combining LSC and MRD showed reduced survival in MRDhigh/LSChigh patients (hazard ratio [HR] 3.62 for OS and 5.89 for cumulative incidence of relapse [CIR]) compared to MRDlow/LSChigh, MRDhigh/LSClow, and especially MRDlow/LSClow patients. Moreover, in the NPM1mutant positive sub-group, prognostic value of golden standard NPM1-MRD by qPCR can be improved by addition of flow cytometric approaches. This is the first prospective study demonstrating that LSC strongly improves prognostic impact of MRD detection, identifying a patient subgroup with an almost 100% treatment failure probability, warranting consideration of LSC measurement incorporation in future AML risk schemes.
引用
- Zeijlemaker W, Grob T, Meijer R, et al. CD34+CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemia. Leukemia. 2018. PMID: 30542144. doi:10.1038/s41375-018-0326-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。